Table 1.
Baseline Demographics of Patients With Versus Without CRT at Enrollment in CHAMPION
| CRT/CRT‐D (n=190) | No CRT/CRT‐D (n=360) | P Value* | |
|---|---|---|---|
| Demographics | |||
| Age, y | 63.8±12.3 (190) | 60.3±13.0 (360) | 0.0039 |
| Sex (% men) | 167 (87.9%) | 232 (64.4%) | <0.0001 |
| Race (% White) | 157 (82.6%) | 244 (67.8%) | 0.0002 |
| Laboratory assessments | |||
| Systolic blood pressure, mm Hg | 117±20 (190) | 125±22 (360) | 0.0001 |
| Heart rate, bpm | 73±11 (189) | 73±13 (360) | 0.2971 |
| Body mass index, kg/m2 | 29.7±6.1 (190) | 31.2±7.3 (360) | 0.0324 |
| Serum urea nitrogen, mg/dL | 31.9±19.0 (178) | 27.2±15.7 (337) | 0.0064 |
| Creatinine, mg/dL | 1.5±0.5 (190) | 1.3±0.4 (360) | <0.0001 |
| Glomerular filtration rate, mL/min per 1.73 m2 | 57.2±21.3 (190) | 63.1±23.4 (360) | 0.0047 |
| Hemodynamics | |||
| Ejection fraction (%) | 25±10 (189) | 31±15 (359) | <0.0001 |
| Cardiac output, L/min | 4.2±1.4 (189) | 4.6±1.5 (359) | 0.0011 |
| Cardiac index, L/min per m2 | 2.0±0.6 (189) | 2.2±0.6 (359) | <0.0001 |
| Pulmonary vascular resistance, Wood units | 2.8±1.9 (189) | 2.7±1.9 (359) | 0.5124 |
| PA mean pressure, mm Hg | 29.8±9.2 (190) | 29.1±10.4 (360) | 0.2136 |
| PA wedge pressure, mm Hg | 19.2±7.7 (190) | 17.7±8.2 (360) | 0.0165 |
| Medical history | |||
| Ischemic cardiomyopathy (%) | 134 (70.5%) | 198 (55.0%) | 0.0005 |
| Hypertension (%) | 138 (72.6%) | 289 (80.3%) | 0.0524 |
| Hyperlipidemia (%) | 153 (80.5%) | 269 (74.7%) | 0.1380 |
| Coronary artery disease (%) | 141 (74.2%) | 243 (67.5%) | 0.1181 |
| Myocardial infarction (%) | 101 (53.2%) | 170 (47.2%) | 0.2093 |
| Diabetes mellitus (%) | 82 (43.2%) | 187 (51.9%) | 0.0595 |
| Atrial tachycardia flutter/fibrillation (%) | 111 (58.4%) | 144 (40.0%) | <0.0001 |
| Chronic obstructive pulmonary disease (%) | 53 (27.9%) | 106 (29.4%) | 0.7668 |
| Treatment history | |||
| CRT‐D/iplantable cardioverter‐defibrillator implant (%) | 190 (100.0%) | 186 (51.7%) | <0.0001 |
| Angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker use (%) | 153 (80.5%) | 274 (76.1%) | 0.2819 |
| Beta blocker use (%) | 173 (91.1%) | 326 (90.6%) | 1.0000 |
CHAMPION indicates CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association Class III Heart Failure Patients; CRT, cardiac resynchronization therapy; CRT‐D, cardiac resynchronization therapy with implantable cardioverter‐defibrillator; and PA, pulmonary artery.
*
P value testing patients with CRT/CRT‐D vs patients without CRT/CRT‐D obtained from exact Wilcoxon rank‐sum test for continuous measures and Fisher's exact test for categorical measures.